Chronic hypercapnia should not exclude patients from lung volume reduction surgery

Area of Science:

• Pulmonary Medicine
• Surgical Outcomes
• Respiratory Physiology

Background:

• Chronic hypercapnia is often considered a contraindication for lung volume reduction surgery (LVRS) due to perceived increased perioperative risks.
• Limited data exists on the specific impact of hypercapnia on postoperative outcomes following LVRS.

Purpose of the Study:

• To analyze the influence of chronic hypercapnia on postoperative outcomes in patients undergoing LVRS.
• To determine if chronic hypercapnia alone should exclude patients from LVRS.

Main Methods:

• A comparative study of 22 patients with chronic hypercapnia (arterial pCO2 ≥ 45 mmHg) and 58 patients without hypercapnia who underwent LVRS.
• Assessment of functional improvement (FEV1) and clinical outcomes (mortality, ICU stay, chest drainage duration) at 3 months post-LVRS.

Main Results:

• 30-day mortality rates were similar between hypercapnic (9.1%) and normocapnic (5.2%) groups (P=n.s.).
• Intensive care unit (ICU) stay and chest drainage duration were comparable between groups.
• Patients with chronic hypercapnia experienced a greater percentage increase in FEV1 (73%) compared to controls (37%) post-LVRS (P=0.0385).
• Higher severity of parenchymal destruction was associated with perioperative mortality in both groups.

Conclusions:

• Chronic hypercapnia alone does not significantly increase mortality or morbidity after LVRS and should not be an exclusion criterion.
• Additional risk factors like disease homogeneity, severe parenchymal destruction, or pulmonary hypertension may warrant contraindication for LVRS.